Anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with solid tumors and gastric/ gastro-esophageal junction adenocarcinoma (G/GEJ AC): A phase study

被引：3
|
作者：
Liu, J. J. [1 ]
Yu, X. [2 ]
Zhang, J. [3 ]
Yang, J. [4 ]
Yue, J. [5 ]
Sun, Y. [6 ]
Pan, Y. [7 ]
Sun, M. [8 ,9 ]
Qin, Y. [10 ]
Shen, L. [11 ]
Song, R. [12 ]
Ruan, J. [13 ]
Zhou, A. [14 ]
Mou, Y. [15 ]
Liu, Z. [16 ,17 ]
Liu, Z. [16 ,17 ]
Morris, M. [18 ]
Aghmesheh, M. [19 ]
Tazbirkova, A. [20 ]
Zhou, H. [21 ]
机构：
[1] St Vincents Hosp Sydney, Med Oncol Dept, Darlinghurst, NSW, Australia
[2] Fudan Univ, Shanghai Canc Ctr, Pancreat Surg, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China
[4] Fujian Prov Hosp, Dept Abdominal Oncol, Fuzhou, Peoples R China
[5] Shandong Univ, Shandong Canc Hosp, Abdominal Radiat Oncoloy 1, Jinan, Peoples R China
[6] Shandong Canc Hosp & Inst, Phase 1 Clin Trial, Jinan, Peoples R China
[7] USTC, Anhui Prov Hosp, Affiliated Hosp 1, Dept Oncol, Hefei, Peoples R China
[8] Shandong First Med Univ, Cent Hosp, Dept Oncol, Taiyuan, Peoples R China
[9] Shandong Univ, Jinan Cent Hosp, Taiyuan, Peoples R China
[10] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China
[11] Beijing Canc Hosp, Gastrooncol Dept, Beijing, Peoples R China
[12] Jiangxi Canc Hosp, Gastrooncol Dept, Nanchang, Jiangxi, Peoples R China
[13] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Med Oncol, Hangzhou, Peoples R China
[14] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Med Oncol, Natl Canc Ctr, Beijing, Peoples R China
[15] Zhejiang Prov Peoples Hosp, Gastroenteropancreat Surg, Hangzhou, Peoples R China
[16] Qingdao Univ, Affiliated Hosp, Dept Oncol, Qingdao, Peoples R China
[17] Hunan Canc Hosp, Gastrourol Dept, Changsha, Peoples R China
[18] Sunshine Coast Univ Private Hosp, Ramsay Hlth, Med Oncol, Oncol, Birtinya, Qld, Australia
[19] Southern Med Day Care Ctr, Dept Med Oncol, Wollongong, NSW, Australia
[20] Pindara Private Hosp, Ramsay Hlth, Oncol, Southport, Qld, Australia
[21] Innovent Biol Inc, Clin Dev, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.311
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
396MO
引用
收藏
页码：S160 / S160
页数：1
相关论文
共 20 条
  • [1] Anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC): Updated results from a phase I study
    Yu, X.
    Zhang, J.
    Liu, J. J.
    Yang, J.
    Yue, J.
    Sun, Y.
    Pan, Y.
    Sun, M. L.
    Qin, Y.
    Shen, L.
    Song, R.
    Ruan, J.
    Zhou, A.
    Mou, Y.
    Aghmesheh, M.
    Morris, M.
    Yu, X.
    Zhao, X.
    Chen, M.
    Tazbirkova, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1456 - S1456
  • [2] A phase 1/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric/gastroesophageal junction cancer.
    Bai, Chunmei
    Xue, Junli
    Zheng, Yi
    Sun, Meili
    Ying, Jieer
    Zhou, Fuxiang
    Yu, Yiyi
    Sun, Yuping
    Xing, Ligang
    Zhang, Yanqiao
    Wen, Jinhua
    Xiong, Jianping
    Wu, Heshui
    Yang, Xiuli
    Wan, Lixin
    Guo, Shiwei
    Zhao, Rusen
    Zhu, Zhizhen
    Gong, Zhihua
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] A phase I/II study of ASKB589 (anti-claudin 18.2 [CLDN18.2] monoclonal antibody) in patients with solid tumors.
    Zhang, Miao
    Gong, Jifang
    Wang, Jufeng
    Shi, Jianhua
    Zhu, Hong
    Wang, Yusheng
    Chen, Yigui
    Wang, Feng
    Qu, Xiujuan
    Yu, Junyan
    Xu, Huiting
    Ma, Jian
    Shen, Peng
    Yuan, Yuan
    Wu, Jianbing
    Cao, Jiaqing
    Chen, Jing
    Hickingbottom, Barbara Diann
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 397 - 397
  • [4] A phase Ib/II study of ASKB589 (anti-Claudin 18.2 [CLDN18.2] monoclonal antibody) combined with CAPOX and PD-1 inhibitor as first-line treatment for locally advanced, relapsed and metastatic gastric/gastro-esophageal junction (G/GEJ) adenocarcinoma.
    Shen, Lin
    Peng, Zhi
    He, Ying
    Chen, Jing
    Hickingbottom, Barbara
    Lu, Jianfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 317 - 317
  • [5] Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: Preliminary results from a phase 1 study
    Yu, Xianjun
    Zhang, Jian
    Tazbirkova, Andrea
    Yang, Jianwei
    Yue, Jinbo
    Sun, Yuping
    Pan, Yueyin
    Sun, Meili
    Qin, Yanru
    Shen, Lin
    Song, Rongfeng
    Ruan, Jian
    Zhou, Aiping
    Mou, Yiping
    Liu, Zimin
    Liu, Zhenyang
    Zhang, Yongchang
    Morris, Michelle
    Aghmesheh, Morteza
    Zhou, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma
    Lordick, F.
    Chao, J.
    Buxo, E.
    van Laarhoven, H. W. M.
    Lima, C. M. R.
    Lorenzen, S.
    Dayyani, F.
    Heinemann, V.
    Greil, R.
    Stienen, S.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S928 - S929
  • [7] Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study
    Zheng, Li
    Dai Ruihong
    Ying Jieer
    Xu, Qi
    Guo, Zengqing
    Hu, Changlu
    Sun, Yuping
    Niu, Zuoxing
    Hao, Jihui
    Zhang, Mingjun
    Dai Guanghai
    Hua, Dong
    Pan, Yueyin
    Wang, Xin
    Wei, Shuqing
    Chen, Xiaobing
    Yu, Xinhe
    Zhang, Yulong
    Zhou, Hui
    Bi, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] CLARITY-Gastric 01: A randomized phase 3 study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC).
    Janjigian, Yelena Y.
    Shitara, Kohei
    Elimova, Elena
    Zhang, Jun
    Chen, Ming-Huang
    Smyth, Elizabeth Catherine
    Lee, Jeeyun
    Miao, Rui
    Liu, Silver
    Holmblad, Marielle
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS507 - TPS507
  • [9] CLARITY-Gastric 01: A randomised phase III study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC)
    Shitara, K.
    Janjigian, Y. Y.
    Elimova, E.
    Zhang, J.
    Chen, M-H.
    Smyth, E.
    Lee, J.
    Miao, R.
    Liu, S.
    Holmblad, M.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S196 - S197
  • [10] CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors.
    Raufi, Alexander G.
    Goyal, Lipika
    Smyth, Elizabeth
    Szekeres, Philip
    Petrone, Marcella
    Hobson, Rosalind
    Thress, Kenneth
    Origuchi, Makoto
    Nehra, Jyoti
    Brown, Jessica S.
    Kumar, Rakesh
    Grenga, Italia
    Barker, Laura
    Janjigian, Yelena Y.
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12